The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication

Phase 1

Recruiting

• Conditions: Peripheral Artery Disease; Claudication, Intermittent; Peripheral Vascular Diseases
• Interventions: Drug: Tetrahydrobiopterin 10 mg/kg; Drug: Tetrahydrobiopterin 20 mg/kg; Drug: L-Ascorbate; Drug: L-Arginine

• Registration Number: NCT04800692
• Lead Sponsor: Louis Messina

Brief Summary

This study will focus on people with claudication from peripheral arterial disease. The investigators are researching whether a multicomponent therapeutic can increase the production of Nitric Oxide in the blood and whether that leads to an improvement in pain free walking distance and overall physical activity.

Detailed Description

The primary objective of this study is to show that ATLAS Therapy, (L-Arginine; Tetrahydrobiopterin; L-Ascorbate) is bioavailable in humans and exerts a measurable effect on its in vivo biological signature, Flow Mediated Vasodilation (FMD) in people with intermittent claudication caused by peripheral arterial disease. This will be a Phase I / dose finding study. All subjects will receive 2 different drug doses of the Kuvan the first 45 days they will receive 10 mg/kg/day. The second 45 days they will receive 20/mg/kg/day.

Study Timeline

• Study First Submitted: 2021-03-11
• Study First Submitted QC: 2021-03-11
• Study First Posted: 2021-03-16
• Study Start: 2021-06-15
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-02
• Last Update Posted: 2025-04-06
• Primary Completion: 2027-07
• Study Completion: 2027-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• PAD as demonstrated by an ABI <0 .9 in one leg or TBI less than <0.7 in patients with an ABI >1.3 (non compressible vessels)
• Rutherford Classification II, III
• Age >18 years old
• Willingness to discontinue phosphodiesterase (PDE) 5 inhibitors such as Viagra, Cialis, Levitra, Revatio
• Willingness to discontinue phosphodiesterase (PDE) 3inhibitors cilostazol, milrinone or Vesnarinone
• Willing and able to comply with all study procedures
• Willing and able to provide informed consent
• Sexually active subjects willing to use an acceptable method of contraception while participating in the study

Exclusion Criteria

• Hypotension defined as a systolic blood pressure less than 100mmhg systolic at screening or baseline visit
• Critical Leg Ischemia (Rutherford Classification IV, V, VI)
• Surgical intervention to alleviate symptoms of claudication in the study leg within the past 6 months or any endovascular interventions within 3 months or who is scheduled to undergo surgical revascularization in the next 6 month
• Walking limited by reasons other than claudication (e.g. arthritis, lung disease, severe neuropathy, lower extremity amputation except single digits)
• Serum creatinine >1.5mg/dl or Hepatic enzymes >2X the upper limit of normal
• Serum potassium greater than 5.0 or use of a potassium sparing diuretic at screening
• Pregnant, breast feeding or planning to become pregnant (subject or partner) at any time during the study.
• Myocardial Infarction, Cerebrovascular Accident or deep vein thrombosis within 12 months of screening
• Known history of nephrolithiasis
• History of ever having a seizure
• Concurrent disease or condition that would interfere with study participation or safety such as bleeding disorders, organ transplant, long term immunosuppression (excluding inhaled steroids), current neoplasm or severe gastroesophageal reflux
• History of vertigo or syncope within the past 10 years
• Enrollment in another drug or device study within 30 days of screening
• Required treatment with a drug known to inhibit folate metabolism (e.g. Methotrexate)
• Taking any of the following medications; PDE3 Inhibitors, PDE5 inhibitors, trental, nitrates, ginkgo biloba, levodopa, warfarin,
• Axillary lymph node dissection
• Presence of an amputation except single digits in either leg
• Preexisting illness that limits ambulation such as severe COPD, class III-IV heart failure, severe arthritis or back pain
• Glucose-6-dehydrogenase deficiency

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Tetrahydrobiopterin Dose 1 (Day 0 to 44)	Tetrahydrobiopterin 10 mg/kg	All subjects will receive 3300mg l-Ascorbate , l-Arginine 3400mg and 10mg/kg of Tetrahydrobiopterin once a day.
Tetrahydrobiopterin Dose 1 (Day 0 to 44)	L-Arginine	All subjects will receive 3300mg l-Ascorbate , l-Arginine 3400mg and 10mg/kg of Tetrahydrobiopterin once a day.
Tetrahydrobiopterin Dose 1 (Day 0 to 44)	L-Ascorbate	All subjects will receive 3300mg l-Ascorbate , l-Arginine 3400mg and 10mg/kg of Tetrahydrobiopterin once a day.
Tetrahydrobiopterin Dose 2 (Day 45 to 90)	Tetrahydrobiopterin 20 mg/kg	All subjects will receive 3300mg l-Ascorbate, l-Arginine 3400mg and 20mg/kg of Tetrahydrobiopterin once a day.
Tetrahydrobiopterin Dose 2 (Day 45 to 90)	L-Arginine	All subjects will receive 3300mg l-Ascorbate, l-Arginine 3400mg and 20mg/kg of Tetrahydrobiopterin once a day.
Tetrahydrobiopterin Dose 2 (Day 45 to 90)	L-Ascorbate	All subjects will receive 3300mg l-Ascorbate, l-Arginine 3400mg and 20mg/kg of Tetrahydrobiopterin once a day.

Primary Outcome Measures

Name	Time	Method
Nitric Oxide bioavailability	90 days	Nitric Oxide bioavailability as measured by flow mediated dilatation (FMD).

Trial Locations

Locations (1)

UMASS Memorial Healthcare - University Campus; 🇺🇸 Worcester, Massachusetts, United States